Anti-CD38-IFNα(att) strongly inhibited MM tumor cell proliferation, although it displayed approximately 20x lower potency relative to native IFNα(IC50s of 95.3 pM and 4.97 pM, respectively; Fig 3C). This evidence concerns the gene CD38 and Miyoshi myopathy.